Ivermectin-Benzimidazole Prescribing Following Celebrity Endorsement (research letter) (2026)

Peer-Reviewed Study · Rockwell MS et al. · May 2026

Rockwell MS et al., 2026-05: A cohort study of 68.4 million US patients found ivermectin-benzimidazole combination prescribing doubled in January-July 2025 compared with the same months of 2024, and rose 2.63-fold among patients with cancer, after the regimen was promoted on a podcast.

Within the cohort of 68 373 949 patients, overall ivermectin-benzimidazole prescribing rates doubled from January 1, 2025, to July 31, 2025, compared with January 1, 2024, to July 31, 2024 (RR = 1.97; 99.5% CI, 1.70-2.29)

Rockwell MS et al., 2026-05: A cohort study of 68.4 million US patients found ivermectin-benzimidazole combination prescribing doubled in January-July 2025 compared with the same months of 2024, and rose 2.63-fold among patients with cancer, after the regimen was promoted on a podcast. C9 latest status on access. Study type: retrospective cohort (TriNetX deidentified EHR); N=68,373,949; country USA; drug exposure defined as same-day prescriptions for ivermectin plus a benzimidazole (albendazole, fenbendazole, mebendazole, thiabendazole); funder/conflicts in full text (not read here); comparator: Jan-Jul 2024 rates. The paper states that 'rigorous clinical trial evidence does not presently support its use, nor does evidence support the use of fenbendazole or other benzimidazoles for cancer therapy'. Quote normalised for thin spaces. Also filed as FBD-24 (claims C3, C9). Study type: controlled study.